دورية أكاديمية
أعرض في EDS

Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort.

التفاصيل البيبلوغرافية
العنوان: Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort.
المؤلفون: da Costa IHF; Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. iwyson@gmail.com.; Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil. iwyson@gmail.com., de Pádua CAM; Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., de Miranda Drummond PL; Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.; Fundação Ezequiel Dias, Belo Horizonte, Minas Gerais, Brazil., Silveira LP; Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., Malta JS; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., Dos Santos RMM; Fundação Ezequiel Dias, Belo Horizonte, Minas Gerais, Brazil., Reis AMM; Programa de Pós-Graduação em Medicamentos e Assistência Farmacêutica, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.; Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil.
المصدر: Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2023 Jul; Vol. 56 (1), pp. 147-155. Date of Electronic Publication: 2023 May 03.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Publishers Country of Publication: Netherlands NLM ID: 9502018 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-742X (Electronic) Linking ISSN: 09295305 NLM ISO Abbreviation: J Thromb Thrombolysis Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Dordrecht ; Norwell, MA] : Kluwer Academic Publishers, c1994-
مواضيع طبية MeSH: Multiple Myeloma*/complications , Multiple Myeloma*/drug therapy , Venous Thromboembolism*/diagnosis , Venous Thromboembolism*/epidemiology , Venous Thromboembolism*/etiology, Humans ; Anticoagulants/therapeutic use ; Cohort Studies ; Brazil/epidemiology ; Risk Assessment ; Risk Factors ; Immunologic Factors/therapeutic use ; Retrospective Studies
مستخلص: Venous thromboembolism (VTE) is among the complications of Multiple Myeloma (MM) and may occur in up to 10% of this patient population. However, medications used in MM therapy such as immunomodulators (IMID) may raise these rates. Thus, risk prediction models have been developed to quantify the risk of VTE in MM patients. The aim of this study is to compare the performance of three risk assessment models for VTE in newly diagnosed MM (NDMM) patients using immunomodulatory agents. A historical cohort study during a 10-year period in a Brazilian metropolis with NDMM treated with IMID. Data were collected from patient's medical charts for the period of one year to calculate the scores using IMPEDE VTE, SAVED, and International Myeloma Working Group (IMWG) guidelines. The area under the curve (AUC) of the Receiver Operating Characteristic curve analysis was calculated to assess the discriminative power of three risk assessment models. We included 131 patients (9 in the VTE group versus 122 in the non VTE group). According to IMPEDE, 19.1, 62.6, and 18.3% of patients were considered low, intermediate, and high risk, respectively. SAVED classified 32.1% as high risk and 64.9% had ≥2 risk factors based on IMWG guidelines. The AUC of the IMPEDE VTE score was 0.80 (95% CI 0.66-0.95, p = 0.002), of the SAVED score was 0.69 (95% CI 0.49-0.89, p = 0.057), and of the IMWG risk score was 0.68 (95% CI 0.48-0.88, p = 0.075). IMPEDE VTE was the most accurate in predicting the development of VTE in Brazilian patients on IMID therapy. The SAVED score and the IMWG guidelines did not show discriminative ability in predicting VTE based on the population involved in this study.
(© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Malta JS, Silveira LP, de Drummond PLM, Costa NL, dos Santos RMM, Reis IA et al (2021) Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma. Curr Med Res Opin. 37(7):1163–1169. (PMID: 10.1080/03007995.2021.192913633979261)
Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: Prophylaxis and risk prediction tools. Cancers (Basel). 12(1):191. (PMID: 10.3390/cancers12010191319409727016665)
Baker HA, Brown AR, Mahnken JD, Shireman TI, Webb CE, Lipe BC (2019) Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Med 8(1):455–462. (PMID: 10.1002/cam4.192730585435)
Talamo GP, Ibrahim S, Claxton D, Tricot GJ, Fink LM, Zangari M (2009) Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Blood Coagul Fibrinolysis 20(5):337–339. (PMID: 10.1097/MBC.0b013e32832b27e619367157)
Palmaro A, Rougé-Bugat ME, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M (2017) Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiol Drug Saf 26(5):578–586. (PMID: 10.1002/pds.418028198064)
Kristinsson SY, Landgren O (2012) Thromboprophylaxis in multiple myeloma: Is the evidence there? Expert Rev Anticancer Ther 12(3):291–294. (PMID: 10.1586/era.11.214223693206816800)
Zangari M, Barlogie B, Cavallo F, Bolejack V, Fink L, Tricot G (2007) Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Blood Coagul Fibrinolysis 18(7):595–598. (PMID: 10.1097/MBC.0b013e3281067fb217890944)
Leclerc V, Karlin L, Herledan C, Marchal L, Baudouin A, Gouraud A et al (2022) Thromboembolic events and thromboprophylaxis associated with immunomodulators in multiple myeloma patients: a real-life study. J Cancer Res Clin Oncol 148(4):975–984. (PMID: 10.1007/s00432-021-03693-534143239)
Kandemir EA, Bayraktar-Ekincioglu A, Kilickap S (2021) Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist’s impact on anticoagulant therapy. Support Care Cancer 29(3):1699–1709. (PMID: 10.1007/s00520-020-05669-632776163)
Sanfilippo KM (2020) Assessing the risk of venous thromboembolism in multiple myeloma. Thromb Res 191(January):S74–S78. (PMID: 10.1016/S0049-3848(20)30401-132736783)
Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S (2019) Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. J Oncol Pharm Pract 25(4):806–812. (PMID: 10.1177/107815521875850029486638)
Carrier M, Le Gal G, Tay J, Wu C, Lee AY (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9(4):653–663. (PMID: 10.1111/j.1538-7836.2011.04215.x21255254)
Jha AK, Larizgoitia I, Audera-Lopez C, Prasopa-Plaizier N, Waters H, Bates DW (2013) The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf 22(10):809–815. (PMID: 10.1136/bmjqs-2012-00174824048616)
Mosaad M, Elnaem MH, Cheema E, Ibrahim I, Ab Rahman J, Kori AN et al (2021) Cancer-associated thrombosis: a clinical scoping review of the risk assessment models across solid tumours and haematological malignancies. Int J Gen Med 14(May):3881–3897. (PMID: 10.2147/IJGM.S320492343350528318782)
Sanfilippo KM, Luo S, Wang TFTF, Fiala M, Schoen M, Wildes TM et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 94(11):1176–84. (PMID: 10.1002/ajh.25603313790007058359)
Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN et al (2019) Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. JNCCN J Natl Compr Cancer Netw 17(7):840–847. (PMID: 10.6004/jnccn.2018.7273)
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B et al (2008) Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423. (PMID: 10.1038/sj.leu.240506218094721)
(IHME) I for HM and E. GBD Results. [Internet]. IHME, University of Washington. 2020. https://vizhub.healthdata.org/gbd-results/ [accessed 2022 Aug 24].
de Crusoé EQ, Pimenta FCF, Maiolino A, de Castro NS, Pei H, Trufelli D et al (2021) Results of the daratumumab monotherapy early access treatment protocol in patients from Brazil with relapsed or refractory multiple myeloma. Hematol Transfus Cell Ther. 43(4):417–23. (PMID: 10.1016/j.htct.2020.07.00532967807)
Silveira LP, de Pádua CAM, de Drummond PLM, Malta JS, dos Santos RMM, Costa NL et al (2021) Adherence to thalidomide in patients with multiple myeloma: a cross-sectional study in a Brazilian metropolis. J Oncol Pharm Pract. 28:373–380. (PMID: 10.1177/107815522199352833583251)
Mandrekar JN (2010) Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol 5(9):1315–1316. (PMID: 10.1097/JTO.0b013e3181ec173d20736804)
Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F et al (2021) Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol 193(6):1213–1219. (PMID: 10.1111/bjh.1750533997961)
Bao L, Wang Y, Lu M, Zhuang J, Chu B, Shi L et al (2022) Validation of the Impede VTE score for predction of venous thromboembolism in Chinese patients with multiple myeloma: a retrospective cohort study. Blood 140(Supplement 1):5146–5147. (PMID: 10.1182/blood-2022-168633)
Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G et al (2020) A real-life survey of venous thromboembolic events occurring in myeloma patients treated in third line with second-generation novel agents. J Clin Med 9(9):1–14. (PMID: 10.3390/jcm9092876)
Chalayer E, Talbot A, Frenzel L, Karlin L, Collet P, Guyotat D et al (2022) Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort. J Thromb Haemost. 20:1–9. (PMID: 10.1111/jth.15758)
Teste A, Thollot H, Tinquaut F, Sotton S, Tardy B, Moreau P et al (2021) PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose? Thromb Res 200:S61–S62. (PMID: 10.1016/S0049-3848(21)00255-3)
Sanfilippo KM, Carson KR, Wang TF, Luo S, Edwin N, Kuderer N et al (2022) Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma. Res Pract Thromb Haemost 6(1):1–7. (PMID: 10.1002/rth2.12634)
Hosmer D, Lemeshow S, Sturdivant R (2013) Applied logistic regression, 3rd edn. Wiley, Hoboken. (PMID: 10.1002/9781118548387)
Oliveira JADQ, Ribeiro ALP, Ribeiro DD, Nobre V, Rocha MODC, Martins MAP (2018) Predictive ability of scores for bleeding risk in heart disease outpatients on warfarin in Brazil. PLoS ONE 13(10):1–15. (PMID: 10.1371/journal.pone.0205970)
Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Campagnaro E et al (2022) Multiple myeloma. Natl Compr Cancer Netw 4(5):1–107.
Baljevic M, Sborov DW, Lim MY, Hillengass J, Martin T, Castillo JJ et al (2022) Optimizing thromboembolism prophylaxis for the contemporary age of multiple myeloma. JNCCN J Natl Compr Cancer Netw 20(1):91–95. (PMID: 10.6004/jnccn.2021.7112)
فهرسة مساهمة: Keywords: Multiple myeloma; Risk assessment models; Venous thromboembolism
المشرفين على المادة: 0 (Anticoagulants)
0 (Immunologic Factors)
تواريخ الأحداث: Date Created: 20230503 Date Completed: 20230623 Latest Revision: 20230623
رمز التحديث: 20240628
DOI: 10.1007/s11239-023-02817-7
PMID: 37133703
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-742X
DOI:10.1007/s11239-023-02817-7